CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 141 enrolled
Drug / intervention
transdermal nitroglycerin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02714205
NCT02714205Phase 2Completed
CompareCT.gov

Flushing Reduction Associated With Nitrates

Alison Huang, MD·interventional·Posted Mar 21, 2016·Updated Mar 28, 2025

In Brief

A Phase 2 clinical trial evaluating transdermal nitroglycerin and Placebo for Menopausal Hot Flashes. Completed, enrolled 141 participants across 2 sites.

Detailed Summary

A randomized, double-blinded, placebo-controlled trial of uninterrupted transdermal nitrate therapy in 140 peri- or postmenopausal women who have frequent hot flashes. Women will be randomly assigned to uninterrupted use of transdermal nitrate therapy (participant directed dose-escalation of 0.2 to 0.6 mg/hr) or identical-appearing placebo patches for 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopausal Hot Flashes
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 21, 2016
Enrollment StartApr 24, 2017
Primary CompletionMar 8, 2022
Study CompletionApr 5, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.3 years ago

Interventions

transdermal nitroglycerindrug

Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.

Placebodrug

Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.